ABSTRACT
Parturition is composed of five separate but integrated physiological events: fetal membrane rupture, cervical dilatation, myometrial contractility, placental separation, and uterine involution. Prostaglandins (PGs) have central roles in each of these events, but the most studied is myometrial contraction. Elevated uterine PGs or the enhanced sensitivity of the myometrium to PGs leads to contractions and labour. The primary regulator of PG synthesis is the mRNA expression of PG H Synthase (PGHS-2 or COX-2). Given the central role of PGs in labour, this enzyme becomes an obvious therapeutic target for the prevention of preterm labour, the major cause of perinatal mortality and morbidity. Unfortunately, even though the non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit PGHS, are usually successful in suppressing preterm labour or prolonging pregnancy in animal and human studies, the NSAIDS have had adverse effects on fetal physiology and development. Therefore, other means to suppress PG synthesis or action to arrest preterm labour need to be investigated. The PGF 2alpha receptor, FP, may prove to be a reasonable target for tocolysis. FP mRNA increases in the mouse uterus at preterm birth, whereas PGF 2alpha concentrations do not increase, suggesting elevated uterine sensitivity to contractile agonists is one mechanism for preterm labour initiation. New data shows that administration of a specific FP antagonist, Theratechnologies (THG) 113 .31, delays preterm birth in mice and sheep with no observable maternal or fetal side effects. Hence antagonizing PG action offers new hope for delaying preterm birth.
THE PRETERM BIRTH PARADIGM AND THE ROLES OF PROSTAGLANDINS IN LABOUR
Preterm birth is the deadliest and most damaging of all the complications of pregnancy, and it is imperative that societal resources be allocated to study and ultimately lower the preterm birth rate. The rate is on the rise in most western countries and is now greater than 9% in parts of Canada (1) and is 12.3% in the United States. (2) It is the leading cause of perinatal mortality and morbidity. Based on data from the Canadian Perinatal Surveillance Report, 81 .6% of all preterm births are low birth weight (LBW, <2500 g at birth), and about 60.0% of all infant deaths occur among LBW/preterm infants.(3) Roughly 20% of preterm infants are thought to be small for gestational age, and these intrauterine growth restricted infants are at greater risk for being delivered before 37 weeks. LBW and preterm delivery are key risk factors for neonatal and infant morbidity, including neurodevelopmental problems, chronic respiratory conditions, infections, and visual and hearing deficits. Furthermore, the lower the gestational age at delivery, the greater the risk for long-term impairment.(4-7) The purpose of this review article will be to tie together the role of the prostaglandins (PGs) and their receptors in the process of term and preterm birth and to discuss some of the current strategies to inhibit PG synthesis or antagonize their actions in attempts to delay preterm labour and prolong pregnancy.
Parturition is comprised of five separate but integrated physiological events: membrane rupture, cervical dilatation, myometrial contractility, placental separation 
. Prostaglandins lead to fetal membrane rupture through the stimulation of matrix metalloproteinase (MMP) activity (9) that leads to extracellular matrix protein remodeling, and they also induce cell apoptosis. (10) A large literature illustrates the roles of PGs in cervical dilatation and ripening. (11) (12) (13) The data are also consistent for a PG role in placental separation. Noort et al.(14) report an association between elevated human PGF 2alpha plasma levels and placental separation, whereas an association exists between PGE 2 administered for induction of labour and placental abruption. (15) In cows with retained fetal membranes due to the non-separation of the fetal and maternal cotyledons, placenta tissue concentrations of PGF 2alpha were significantly lower than in normally separated cotyledons at 6h after parturition. (16) Increasingly the human decidua is being recognized as a site of PGF 2alpha action. Prostaglandin F 2alpha stimulates the production of MMP-2 and -9 and decreases the production of the progesterone receptor isoforms, A, B and C (17, 18) and these actions indirectly lead to the termination of pregnancy. Uterine involution is very closely associated with plasma levels of PGF 2alpha in cows and sheep, (19, 20) and the administration of PGF 2alpha promotes uterine involution in cows. (21) However, the largest amount of information about PGs in parturition addresses their role in promoting myometrial contractility.
UTERINE ACTIVATION GENES AND THEIR PROTEINS
It is well accepted that myometrial contractile activity at birth is the product of enhanced uterine activation and increased levels of contractile stimulators. (22) Several uterine activation genes and their proteins (UAPs) enhance the ability of the myometrium to respond to contractile agonists and to develop and propagate the depolarization signal efficiently between smooth muscle cells. These UAPs include the oxytocin receptor (OTR), PGF 2alpha and PGE 2 receptors (FP, EP [1] [2] [3] [4] , and the primary gap junction protein, Connexin-43 (Cx-43). We now add prostaglandin endoperoxide H synthase (PGHS-2) to this group due to the similarities in expression with the other UAPs, (23) and recent evidence from our laboratory demonstrates that both protein mass and enzymatic activity of the matrix metalloproteinases, MMP-2 and -9, increase in human decidua. The contractile stimulators include oxytocin and PGs. (22) The PGs are now recognized as the "triggers" of labour (24) because the myometrium contracts in response to exogenous PGs in vivo and in vitro, (25) (26) (27) PG synthetic enzymes and levels in tissues and fluids increase before or at the time of labour,(28-34) and inhibitors of PG synthesis delay birth and prolong pregnancy. (24,35) 
PROSTAGLANDIN SYNTHESIS, METABOLISM AND TRANSPORT
Prostaglandins are 20-carbon chain fatty acids that function as local hormones and are produced by all cells of the body. Biologically active eicosanoids (PGs, leukotrienes, lipoxins, and other 20-carbon fatty acids) are formed from the polyunsaturated fatty acid, arachidonic acid (5,8,11,14-cis eicosatetraenoic acid). Arachidonic acid is a common constituent of phospholipids in all cell membranes, cholesteryl esters and triglycerides. The liberation of arachidonic acid from phospholipids is the initial step in the synthesis of PGs. This is accomplished directly by the catalytic action of members of the phospholipase A 2 (PLA 2 ) family of enzymes, or indirectly by the action of phospholipase C (PLC). PLA 2 is present in extracellular types I-IV as well as cytosolic PLA 2 forms, but only Type II PLA 2 (PLA 2 II), Type IV PLA 2 and cytosolic PLA 2 (cPLA 2 ) have been identified in the human gestational tissues at present. The majority of the data to date is on PLA 2 II. PLA 2 II mRNA and immunoreactive protein is present in the placenta, choriodecidua and amnion. PLA 2 II increased with labour in the amnion and placenta, and PLA 2 II enzyme activity increased with labour in the amnion, choriodecidua and placenta(36,37) Rice proposed a model to explain the initial step in the synthesis of PGs.(38) Extracellular (or secreretory) Type II PLA 2 is released by the gestational tissues and acts extracellularly to metabolize phospholipid substrates in the outer leaflet of the plasma membrane. Fatty acid metabolites, especially arachidonic acid, become available for intracellular processing following sn-2 hydrolysis. Arachidonic acid is then available for oxygenation by either of PGHS-1 or -2. Exogenous PLA 2 or arachidonic acid stimulates prostaglandin synthesis, supporting this proposed model.(38) Also, cPLA 2 shuttles between the cytoplasm (inactive form) and the cell membrane (active form) and may therefore also contribute to the hydrolysis of arachidonic acid.(38)
The second step in PG synthesis is the oxygenation and reduction of arachidonic acid to form an unstable intermediate endoperoxide. This step is catalyzed by PG H synthase (PGHS or cyclooxygenase, COX). Two isoforms of PGHS have been identified and well studied, PGHS-1 and -2 (COX-1 and COX-2). They are both homodimeric, haeme-containing, glycosylated proteins which catalyze two enzyme reactions, a cyclooxygenase reaction and a peroxidase reaction, forming, first, PGG 2 , which then undergoes a two electron reduction to PGH 2 .
Inhibitors of PGHS enzymes decrease synthesis of all PGs and are known as the non-steroidal anti-inflammatory drugs (NSAIDs).
The third enzymatic step of PG synthesis is the conversion of PGH 2 to one of the biologically active PGs (D 2 , E 2 , F 2alpha , I 2 , or TXA 2 ) by specific PG synthases. An increase in PGF synthase mRNA relative to PGE synthase mRNA was noted in the sheep placenta at term or dexamethasone-induced delivery,(39) although researchers have little evidence to suggest that this step is either rate limiting or regulated in the human fetal membranes. (40) We believe there may be some regulated isomerase or reductase activity in the human decidua, but further research is necessary to demonstrate a role in parturition. A PG transport protein (PGT) has been discovered in bovine uterus and fetal membranes. Its expression is higher in caruncles (placentae) than elsewhere, and in this tissue only its expression increases in late gestation. It was first proposed and cloned in 1996 when it was determined that PGT avidly facilitates the uptake of PGD 2 , PGE 2 and PGF 2alpha into cells.(52) The transporter has also been identified in human endometrium throughout the menstrual cycle and in decidualized endometrial stromal cells,(53,54) and although it is found in human placenta,(52) it has not yet been well characterized in the pregnant or parturient human uterus. The precise role of this transporter in parturition has not been determined, although it is speculated that it may facilitate PG transfer across the uterus and the metabolism of PGs.(55)
Prostaglandin Endoperoxide H Synthase
Considerable attention has been addressed towards inducible PGHS in recent years and its association with term and preterm birth. As mentioned, it catalyses the second step in PG synthesis: the oxygenation and reduction of arachidonic acid to an unstable intermediate endoperoxide. PGHS-1 and -2 catalyze, first, a cyclooxygenase reaction to form PGG 2 , and then a peroxidase reaction to reduce PGG 2 to PGH 2 . The mature, processed forms of PGHS-1 and -2 have a great deal of homology in their 576 and 587 amino acids, respectively,(56) between 60-65% identity between isoforms within a species and 85-90% sequence identity for similar isoforms between species. The main exceptions are six residues in from the C-terminal region of PGHS-2, an extra 18 amino acids are inserted. The last four may facilitate binding to the nuclear and endoplasmic reticulum membranes or the entire insertion may mark the isoform for rapid proteolysis.(57) PGHS-2 also lacks 17 amino acids that are present in the N-terminal region of PGHS-1. However, the amino acid residues thought to be important for catalysis are conserved, (58) and the two isoforms have about the same affinity (K m ) and capacity (V max ) to convert arachidonic acid to PGH 2 . (59) The single best characterized distinction between PGHS-1 and PGHS-2 is their differential regulation of expression. PGHS-1 can be detected in most tissues although not within all cells of a tissue and is therefore considered to be 'constitutive,' or constantly expressed.(60) On the other hand, PGHS-2 is found at variable levels in tissues and is expressed only in response to cytokines, growth factors, or tumor promoters,(61) hence it is known as the 'inducible' enzyme. PGHS-2 is more highly concentrated on the nuclear envelope than PGHS-1,(62) and oxygenates lower concentrations of arachidonic acid (<1mM) more efficiently than PGHS-1, (63) suggesting that arachidonate can be streamed within a cell for preferential oxygenation by PGHS-2. Cortisol and synthetic glucocorticoids can stimulate cultured human amnion cell PGHS-2 mRNA and protein expression as we showed. (64) PGHS-2 mRNA is present in human fetal membranes, decidua and myometrium and increases before labour onset.(28-34) The X-ray crystallographic forms of PGHS-1 and -2 are nearly superimposable. But it is the substitution of valine in PGHS-2 for isoleucine in PGHS-1 at positions 434 and 523 (the residues in PGHS-2 are given the equivalent number as their counterparts in PGHS-1) that permits the design of inhibitors that are specific for PGHS-2 or -1. In PGHS-2, the smaller size of the Valine at amino acid position 523 exposes a side-pocket off the main substrate channel, which increases the volume of the PGHS-2 active site, a fact that is exploited to produce specific inhibitors of PGHS-2. The longer side chain of isoleucine in PGHS-1, on the other hand, prevents access to this side pocket and thereby considerably lowers specificity of PGHS-2 inhibitors or nonselective non-steroidal antiinflammatory drugs (NSAIDs) to PGHS-1. (65) Hence, several specific inhibitors of PGHS-1 and -2 have been developed.
A third distinct isoform of PGHS has been discovered, PGHS-3 or COX-3.(66) Along with a partial COX-1 protein, it is derived from PGHS-1 but retains intron 1 in its mRNA. It is found in the cerebral cortex of dogs followed by heart and in lesser amounts in other tissues including placenta and fetal tissues. COX-3 is inhibited more readily by acetaminophen than is PGHS-1, but aspirin and indomethacin are among its most potent inhibitors. Indeed, its presence was predicted by the properties of acetaminophen, an NSAID with potent antipyretic and analgesic actions, but relatively little anti-inflammatory function, which was not characteristic of other NSAIDs that are better inhibitors of PGHS-1 or -2. (67,68) At this time there is no evidence that COX-3 synthesizes PGs for the physiological processes of birth.
Sites of prostaglandin synthesis
Prostaglandins are produced in many vertebrate tissues, including the intrauterine tissues. In humans, the sites of prostaglandin synthesis have been studied at term caesarian-section (CS) and at term spontaneous labour (SL). PGE 2 , PGF 2α , and 6-keto F 1α (the stable metabolite of PGI 2 ) are produced in the amnion, chorion, decidua, and placenta at term CS (69, 70) . A significant increase in PGE 2 , PGF 2α , and 6-keto F 1α occurs at SL compared to at term CS in the amnion and chorion. (71) However, we found that there is no significant increase in PGE 2 , PGF 2α , and 6-keto F 1α at SL compared to CS in the decidua or placenta. (71) Skinner and Challis, on the other hand, found that PGE 2 and PGF 2α output increases at SL in the decidua. (70) During cervical ripening PGE 2 production rose in the cervix. (72)Mitchell et al. measured PGD 2 production in the amnion, chorion, decidua, and placenta and found that it was present before the onset of labour (CS) in all four tissues, but production did not significantly increase at SL. Interestingly, production of PGD 2 was three-fold greater in the placenta than in other tissues studied. (72) 
Prostaglandin synthesis regulation and labour
Prostaglandin synthesis regulation is a changing dynamic that is dependent upon the time of gestation and the nature of its stimulatory factors. This is clearly evident when preterm and term parturition are examined. One example is the abundance or activity of PG synthetic or metabolic enzymes and concentrations of maternal plasma and fetal amnion tissue and fluid PGs. For instance, the concentrations of tissue PGE 2 and PGF 2alpha in amnion and placenta are significantly lower at preterm birth (<37 weeks gestation) than at term birth. (73) This is due to the specific activity of PGHS-1 and -2, which we showed is considerably lower at preterm labour than at term labour in human fetal membranes. The specific activity in the human amnion rises from 6±2 to 28±7 pg PGE 2 /microgram protein/min in women delivered by cesarean section preterm but not in labour to those following spontaneous preterm labour. (74) This contrasts to the term birth levels, which are much higher, rising from 18±4 to 39±6 pg PGE 2 /microgram protein/min in women delivered by elective cesarean section at term to those delivering spontaneously at term. The situation in the chorion is similar except that the preterm levels rise proportionally less, from approximately 9±2 to 22±3 pg PGE 2 /microgram protein/min compared to from 17±3 to 32±2 pg PGE 2 /microgram protein/min (all increases are p<0.05) at term labour.(29,32,75) These data are confirmed by Sadovsky et al.(76) whereby they showed that although human amnion PGHS-2 protein mass and PGE 2 concentrations rise with labour at preterm or term, the levels at preterm labour are equal to or lower than in non-labouring term tissues. Hence the PG synthetic capacity of membranes is considerably lower at preterm birth than at term birth when there are no signs of infection.
These fetal membrane PGs may interact with receptors in the fetal membranes (77) or diffuse or be transported to decidua or myometrium. However, a high level of chorionic prostaglandin 15-hydroxy dehydrogenase (PGDH), the primary enzyme that catalyzes PGs into inactive metabolites, prevents intact PGs from the fetal or maternal compartments from crossing over to the other side.(51,78) In light of information (below) regarding high decidual PG synthetic capacity throughout gestation, this metabolic barrier may be acting opposite to conventional thought, that is it may prevent maternal PGs from interacting with fetal membrane PG receptors which might lead to activation of mediators, such as MMPs, (9) that promote membrane rupture. In pathological (infected) preterm birth or in about 15% of idiopathic preterm births, however, the specific activity of PGDH in chorion decreases, potentially allowing greater diffusion or transport of PGs across the chorion to facilitate myometrial contraction. (79) This capacity for PGs to traverse the chorion intact under these conditions remains to be shown directly.
The PGHS synthetic capacity in decidua throughout gestation is different than in fetal membranes. Neither PGHS-1 nor -2 mRNA abundance, enzyme activity or protein concentrations change in decidua during gestation or with labor onset in women.(29,76) The specific activity of (total) PGHS is very high (111±3 pg PGE 2 /microgram protein/min) in decidua, about 3-to 4-fold greater than in fetal membranes. Some controversy exists whether PG concentrations or output from the decidua increase with term labour onset as some studies showed no changes(69,76) while others suggest that there is an increase in PG output from decidual cells with labour at term, (80, 81) which may reflect changes in the specific PGE and F synthases. One report indicates there is no increase in PG output in decidua with preterm labour. (76) The human myometrium does demonstrate an increase in PGHS-2 mRNA with term labour onset,(34) but no increase in PGE2 output occurs with preterm or term labour. (76) The myometrium produces mostly PGI 2 , which was not examined, and which more likely has an effect upon vascular tone than uterine contractility. (24) Prostaglandin synthesis changes in tissues obviously lead to changes in PG concentrations in fluids, which provide more valuable information about the changing nature of PG synthesis. Evidence exists to suggest that amniotic fluid PG concentrations may be relatively low at some preterm births, an observation that reflects the low synthetic capacity of amnion at preterm birth without infection. Romero and Mitchell and others (82) showed that amniotic fluid levels of PGE 2 did not rise at preterm labour compared to not-in-labour matched controls (the mean values were actually lower), but PGF 2alpha concentrations did increase from 252±53 pg/ml to 731±363 pg/ml, although this rise was not statistically significant. Only with infection-associated preterm labour (which occurs in 30-40% of all preterm births) was there a significant increase in amniotic fluid PG levels. During normal birth maternal plasma levels of the PGF 2alpha metabolite, PGFM, rise with cervical dilatation, increasing considerably from late pregnancy not in labour (59±8 pg/ml) to 143±32 pg/ml in early labour and 283±55 pg/ml in late labour. In contrast, the plasma levels were 63±17 pg/ml in preterm labour without infection, which were not different from term notin-labour values. (83, 84) Another key association with PG synthesis that changes as gestation advances is the infection rate. For instance, 70% of spontaneous preterm birth ≤ 30 weeks gestational age is associated with intrauterine infection, whereas after 30 weeks a decreasing rate from 40 to 30% (at term) of spontaneous birth is associated with infection.(85) Pregnancies and births associated with infection are characterized by increased levels of cytokines (interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-α) in the fetal membranes,(86) amniotic fluid,(87-90) lower genital tract, (91) and in the lower segment of the uterus(92) Interestingly, normal pregnancies in the third trimester and term deliveries without infection are also associated with increased levels of IL-8 in myometrium (93) and increased levels of IL-1beta and IL-8 in the amnion and choriodecidua(94) This is particularly relevant as the synthesis of PGs is stimulated by inflammatory agents (95, 96) , which leads to increases in intrauterine fluid and tissue concentrations of PGs and a decrease in PG metabolism. (79) It is clear therefore, that the conditions associated with and responsible for PG synthesis change as gestation advances. When infection is not present, preterm labour is characterized by very low PG synthetic capacities and concentrations and very high metabolic capacities. Conversely, when infection is present, PG synthesis and levels are very high, and metabolism is decreased.
In the situation of preterm labour without infection, when PG levels are very low and at the levels of intact non-labouring term pregnancies, the question derives of how do PGs lead to the initiation and maintenance of labour? We have data in the mouse at preterm labour induced by ovariectomy, (97) ethanol,(23) or lipopolysaccharide(98) that uterine PGF 2alpha concentrations do not increase above levels in age-matched pregnancyintact non-labouring controls -a situation similar to humans without infection. However, the uterine mRNA expression for FP, the PGF 2alpha receptor, increases significantly, suggesting that uterine sensitivity to PGs increases rather than the absolute level of PGs. But these deliveries are dependent upon PG synthesis as administration of the specific PGHS-2 inhibitor, NS-398, delays preterm labour.(99) Thus the threshold for uterine responsiveness to PGs is lowered. By extension, it is possible that enhanced human uterine responsiveness to low concentrations of PGs at preterm in the absence of uterine infection may be responsible for the initiation and maintenance of labour.
Inhibiting PGHS-2 and other strategies to delay preterm birth
Because investigators and caregivers are realizing just how multifactorial and complex preterm birth is, the strategies for dealing with it are evolving into early and late interventions. Early intervention strategies are approaching the problem through dealing with maximizing the environment for pregnant women such as improved antenatal care and lifestyles. Late interventions are largely pharmacological with the intention of decreasing the preterm contractions of the uterine myometrium. One of the goals of late interventions has been to achieve a delivery delay of 48 hours for transport to a tertiary center and administration of glucocorticoids for lung maturation. But clearly, the potential for the late intervention strategy can be much more. Prostaglandins, the "triggers of parturition," (24) have been at the center of late intervention attempts to delay preterm labor. Administration of nonspecific PGHS inhibitors or inhibitors specific to PGHS-2 decrease uterine contractility, in vitro, (76) and delay birth and prolong pregnancy, in vivo, (24, 25) confirming the central role of PGs in labour initiation at term and preterm (Figure 1 ).
Although early trials showed that NSAIDs delayed preterm birth by 48 hours,(14,100) other trials revealed an association between NSAIDs and adverse fetal effects including oligohydramnios, patent ductus arteriosus, necrotizing enterocolitis, intraventricular hemorrhage, persistent pulmonary hypertension of the newborn, (19) and renal failure. (20, 21) Revived hope emerged when studies in the mid 1990's demonstrated that much of the PGs synthesized by intrauterine tissues at preterm labor were derived from the inducible isoenzyme PGHS-2. This discovery provided new hope for the delay in labour since several very specific inhibitors of PGHS-2 that had little effect on PGHS-1 activity existed. If these inhibitors could selectively inhibit uterine PGHS-2 activity, then perhaps preterm birth might be delayed with minimal side effects upon the fetus. The first observational trial using a specific PGHS-2 inhibitor, Nimesulide, appeared to be beneficial in women at high risk of preterm delivery. There were no long-term adverse effects; Nimesulide did not constrict the ductus arteriosus, but oligohydramnios was present in 54% of the patients.(101) Unfortunately in another study from this group, administration of the specific PGHS-2 inhibitor, Rofecoxib (Vioxx), to women at risk of preterm delivery in a randomized, double-blind, placebo-controlled study led to reversible renal effects and did not delay preterm birth.(102) Hence reversible oligohydramnios is a consistent consequence of PGHS-2 inhibition, but delay of preterm birth is inconsistent. It is doubtful prolonged administration of PGHS-2 inhibitors will ever be recommended.
However, lower doses of selective PGHS-2 inhibitors or intermittent administration of these compounds might prove effective along with combining treatments with other drugs. For instance, 200 mg/day Celecoxib, half the normal test dose, in combination with an epidermal growth factor receptor tyrosine kinase inhibitor, Tarceva (Erlotinib), has proven effective in treating mouse models of colon cancer.(103) This information might apply also to managing preterm labor, as we demonstrated a few years ago that tyrosine kinase inhibitors (tyrphostins) were as effective as the PGHS-2 inhibitor, NS-398, in preventing LPS-induced preterm birth in mice. (104) Unfortunately, a 48-hour delay to improve immediate fetal outcome is a long way from decreasing the overall preterm birth rate in western society, and thereby improving many long term infant outcomes. It is uncertain whether the synthesis of all PGs can be inhibited. In fact, this might be the wrong strategy. PGHS inhibitors have a limited ability to differentiate between those PGs important in maternal and fetal physiological and developmental processes and those that are responsible for labor itself. Another, and perhaps better, strategy to block PG synthesis is to antagonize the activity of a single PG, rather than many PGs. This antagonism is possible through the inhibition of specific PG receptors.
PROSTAGLANDIN RECEPTORS
Prostaglandins were originally thought to interact directly with the cell membrane, thereby altering its characteristics and modulating cell physiology. However, their different activity profiles and generation of second messengers, principally cyclic AMP (cAMP), phosphatidylinositol turnover and Ca 2+ shifts, suggested that they interact with discreet receptors and that different receptors exist for each PG. (110) In the 1980s, studies by Coleman and colleagues using specific antagonists further characterized these receptors pharmacologically.(111) They classified the receptors as one each for PGs D 2 , F 2alpha , I 2 , and TXA 2 , as DP, FP, IP, and TP, and four for PGE 2, as EP [1] [2] [3] [4] . The first of these receptors that was isolated and cloned was the TP receptor. (112) The protein is a G-protein linked member of the rhodopsin family of receptors with seven transmembrane domains. Subsequently, homology screening using mouse cDNA libraries led to the identification of the structures of all eight receptors, (113) each encoded by a different gene. More recently, several splice variants have been identified for human EP 3 (8 isoforms), sheep and bovine FP (2 isoforms),(114) rat EP 1 (2 isoforms), and human TP (2 isoforms)(115) They vary largely in their cytoplasmic C-terminal regions where coupling with G proteins occurs. The amino acid sequences have been fully described for human and mouse receptors, and partially described for rat and sheep. There is only 20-30% homology between amino acid sequences of various receptors within a species, but 79-89% homology exists between like receptors of different species.
Prostaglandin F 2α action is mediated by the FP receptor, which is coupled to G-protein mediated signal transduction pathways leading to the mobilization of intracellular Ca
2+
. 4 , and IP are relaxatory receptors.
Prostaglandin receptors in pregnancy and birth
PG receptor expression varies considerably from the non-pregnant state to pregnancy to birth, and the relative level or type of receptors may dictate the degree of uterine quiescence or contractility. The expression of the contractile EP 3 gene in pregnant human myometrium was 40% less than that in non-pregnant myometrium, and expression of the FP gene in human myometrium also decreased during pregnancy by 45% compared to levels in non-pregnant myometrium.(118) Similarly, uterine FP mRNA expression was much lower in pregnant than nonpregnant myometrium(118) and declined significantly with gestational age in patients not in labor and then at term increased significantly with labor.(119) These data correlate very well with the in vitro human myometrial contractile data. The contractile ED 25 for PGF 2α administered to non-pregnant human myometrium, in vitro, was 0.04 nmol versus the much higher 0.5 nmol in nonlabouring term tissue. The values were similar for contractile PGE 2 responses suggesting the number of contractile receptors is reduced during pregnancy to maintain uterine quiescence. (25) (26) (27) Conversely, labour in the pregnant baboon myometrium was associated with a lower abundance of the relaxatory EP 2 receptor mRNA, (120) and similarly in the rat uterus, EP 2 expression increased during pregnancy then decreased in labour. (121) In the myometrium of pregnant rats, expression of FP mRNA increased significantly from late gestation until delivery, returning to prepartum levels by one day postpartum while the levels of the relaxatory EP 2 receptor were the inverse to those of FP. (122) In one exception, rat myometrial FP mRNA levels were higher on GD18 than in nonpregnant tissues, but were statistically similar to high term levels and may have already begun the labourassociated rise. (121) In one study the myometrium of the sheep displayed a significant increase in the mRNA expression of FP and EP 3 with the onset of labour at term, but interestingly, there was also an increase in the relaxatory EP 2 , which may have some role for passage of the fetus (see below). (123) Another ovine study did not observe any changes in FP or the four EP receptor subtypes in myometrium at term, suggesting that changes in the expression of these receptors may not be large and subject to both stimulatory and inhibitory influences. (124) The maintenance of pregnancy is likely related to an increase in relaxatory EP receptor responses (primarily EP 2 )(27) as well as increased coupling of G αs to adenylate cyclase, (125) because there is much less of this coupling at parturition. These events correlate with an increase in EP 2 mRNA expression in the myometrium of women late in gestation, and not in labor, when compared to women at term not in labor. (119) Data from pregnant baboons(120) (as mentioned above) and mice(126) support these findings. Thus, myometrial active quiescence may change to an active contractile state in concert with an up-regulation of contractile receptors and loss of relaxatory receptors and decreased cAMP production.
The location of receptors within the tissue may also be important for uterine function. Contractionpromoting EP 1 and EP 3 receptors are found in greater abundance in the fundus whereas relaxation-promoting EP 2 and EP 4 receptors are found in the lower uterine segment, (127) where they may be involved in uterine relaxation to allow passage of the fetal head and shoulders. However, the lower segment responds by contraction to PGF 2α challenge and lower doses of PGE 2 in in vitro studies, (27) so it may have the dual function of contraction and relaxation.
Only one study has examined the relative levels of myometrial PG receptors at human preterm birth. (122) FP mRNA levels from lower uterine segment myometrium were higher at preterm birth with and without labour than at term without labour. The EP 2 mRNA levels were highest at preterm not in labour and decreased to term. None of the patients had clinical signs of infection, but a direct examination of tissues or amniotic fluid for signs of infection (128, 129) or stratification of patients to gestational age is warranted to identify more subtle changes in the gestational situation. Such information may provide clues as to potential regulation of the genes for the PG receptors.
Mechanisms regulating prostaglandin receptor expression
Surprisingly, there is little work published on the regulation of the PG receptors in uterine myometrium. Interestingly, in rat, FP rose in pregnancy compared to the nonpregnant state, but rose even more during labour. (121) Administration of the progesterone receptor antagonist, RU486, increased FP and decreased EP 2 mRNA. Further, antagonism of estrogen action decreased FP mRNA whereas administration of estradiol enhanced FP expression. Progesterone administration alone promoted EP 2 expression, and when this was supplemented with estradiol, the increase was greater. Hence steroids regulate PG receptors in the rat. (121) Similarly, little is known of the cellular regulation of PG receptors. Some information may be available from studies examining the other UAPs that have implicated pro-inflammatory cytokines in their regulation. For instance, PGHS-2 mRNA increases in human myometrium prior to the onset of term labour,(34) and transcription of PGHS-2 is stimulated by IL-1beta through activation of the transcription factor, NFκB. (130) In cultured human ULTR myometrial cells, IL-1beta (10 ng/ml for 24h) stimulated an 8-fold increase in FP mRNA abundance compared to untreated control levels (6.87±1.69 units normalized to GAPDH vs. 0.85±0.12 units, n=4, p<0.05). (131) In addition, evidence of FP regulation was found through characterization of the FP promoter. We isolated, cloned and sequenced a ~4.1 kb fragment containing intron 1, exon 1 and ~2. 
FP receptor
The FP gene has been sequenced from human,(116) bovine,(136) mouse, (137) and sheep, (138) and there is general agreement in the literature on its structure. The gene is approximately 10 kb in length and is composed of 3 exons separated by 2 introns. The translation initiation start site is located within exon 2, while exon 1 is non-coding and exon 3 also contains large regions of non-coding sequence. Two mRNA species are reported to arise from alternative splicing within exon 3 of the ovine FP gene, and have been called the FP A and FP B isoforms. (114) 
Effect of FP knockout in mice
Mice in which the FP gene is deleted become pregnant, but hold their pups past normal term because luteolysis is prevented and the fall in progesterone does not occur. (97, 139) However, ovariectomy on GD19 in FP knockout mice leads to a precipitous drop in circulating progesterone concentrations and normal birth at term on GD20(140) that is associated with mRNA increases in both OTR and PGHS-2. These data appear to be contradictory to the notion that FP is a key component to labour because it is dispensable to the birth process. However, when the other uterine activation proteins are examined, none can be proven to be essential to the birth process. The oxytocin knockout mouse delivers at term birth; (141, 142 ) the OTR knockout is lethal to the embryonic mouse (Lou Mugliapersonal communication); the PGHS-1 knockout mouse does not deliver on time, but that is due to the loss of PGF 2α for luteolysis;(143,144) the PGHS-2 knockout mouse rarely survives to adulthood, but when it does, it cannot reproduce because PGHS-2 is required for ovulation; (145, 146) and connexin-43 (CX-43) knockout fetuses die at birth as a result of a failure in pulmonary gas exchange caused by a swelling and blockage of the right ventricular outflow from the heart. (147) We used other means, therefore, to address the need for the four uterine activation proteins in mice by studying their mRNA levels and uterine PGF 2alpha concentrations at term birth, preterm birth induced by ovariectomy, and under conditions in which birth was delayed at term by an implanted pellet that released Figure 2 . A prostaglandin F 2alpha receptor antagonist administered to the mother is effective because it arrests several parturition-related PGF 2alpha actions in maternal tissues. The PGE 2 actions (membrane rupture and cervical dilatation) would not be arrested.
progesterone at a low rate.(148) These treatments created conditions of variable expression of the UAPs. These data demonstrated that the FP receptor mRNA increases at each birth -preterm, term and postterm, that its expression is decreased at expected term birth when elevated P 4 levels blocked birth, and that it is the only UAP that exhibits these characteristics. Further, birth occurs if expression of three of the four UAPs are increased, suggesting that redundant mechanisms affect birth. But when only two of the UAPs increase their expression, birth does not occur. Thus it may be possible to delay preterm birth by blocking the expression or action of two of the UAPs. By extension, antagonizing the activity or action of either PGHS-2 or FP effectively blocks two of the UAPs, and this may be the reason selective PGHS-2 inhibitors are so effective in delaying preterm labour(35). This concept also predicts that antagonizing the FP receptor will delay preterm labour. The following studies tested this concept using a specific antagonist of FP action.
A specific FP receptor antagonist
THG113 (Theratechnologies, Montreal, PQ) is a specific, noncompetitive, reversible peptide inhibitor of the FP receptor that blocks the interaction of the receptor with G alpha q , ultimately preventing the increase in intracellular [Ca 2+ ]. It binds specifically to FP-expressing but not to native (non FP-expressing) HEK293 cells. (149) In FPexpressing HEK293 cells, THG113 significantly reduces PGF 2alpha -induced IP 3 generation with an IC 50 of 30 nM. Similarly, PGF 2alpha -stimulated retinal arteriole contraction is non-competitively blocked (ca. 90%, IC 50 340 nM) by THG113 whereas neither agonists requiring homologous receptors (PGE 2 (EP 1 receptor) and U46619 (TP receptor)) nor numerous other contractile agents (e.g. PAF, endothelin, or angiotensin II) are affected by THG113. Only 1% or less crosses the mouse placenta (Dr. K. Peri, Theratechnologies, personal communication), a labyrinthine, hemotrichorial model (two layers of syncytiotrophoblast and a single mononuclear cell layer). (150) The rate of transfer across other placenta types, especially the hemochorial human placenta, is unknown, but hopefully is small, thereby minimizing the effect of THG113 upon the fetus and qualifying THG113 as a candidate tocolytic.
THG113 was effective in delaying preterm birth induced by administration of LPS (50 microgram, ip, twice at 3 h interval) on GD 16 to pregnant mice. (149) In control dams, preterm birth occurred within 18h of LPS administration in 100% of cases. THG113 administered (10 micromol/kg bolus followed by 0.8 micromol/kg/h) 4-6h after administration of LPS, when the PG effect of luteolysis was past, delayed preterm birth >40h in LPStreated dams by antagonizing PGF 2alpha responses in the uterus. Fetuses from THG113 treated dams were born alive with higher birth weights than control-treated dams and appeared healthy.
Increases in the abundance of contractile FP and EP 3 mRNA and in the relaxatory EP 4 mRNA were evident in sheep myometrium at term in one study (123) but not in another study (124) . No studies have explored the changes in receptors at preterm birth in sheep to our knowledge. We therefore determined that a variant of the FP receptor antagonist, THG113.31, is effective in delaying RU486-induced preterm labour and delivery in a sheep infused for 9h (the length of the infusion) beyond the time an untreated ewe delivered, indicating that FP is involved in generating uterine contractile activity at preterm labour. (151) The effectiveness of this FP antagonist is likely due to the multiple roles of PGF 2alpha in mediating several of the physiological effects of labour. (Figure 2) 
NUCLEAR FACTOR-KAPPA B -INVOLVEMENT WITH PG SYNTHESIS-RECEPTOR CASCADE
Considerable evidence accumulated since 1999 has shown that the nuclear transcription factor, nuclear factor-kappa B (NF kappa B), is involved with many aspects of PG synthesis and action in the intrauterine tissues. The NF kappa B family of transcription factors is associated with inflammation and can be activated by the pro-inflammatory cytokines associated with labour to affect PG synthesis in uterine-derived tissues and cells. This mechanism includes TNF-alpha, (152, 153) IL1beta, (130) and LPS, (154) although this latter effect is not always consistent.(155) It appears that ΝF kappa Β mediates IL-1beta action at several levels of the PG synthesis-receptor cascade, including secretory type II PLA 2 ,(154) PGHS-2, (130, 153, 156) and the FP receptor. (131) The possibility exists that NFκB may also regulate specific PG synthases and PG metabolism (PGDH), but there is no evidence at present to support or refute this notion. An inhibitor of NF kappa B, SN-50, was able to delay preterm birth when administered into the amniotic fluid of mice, (157) and infusion of sulfasalazine, an anti-inflammatory and NF kappa B inhibitor, decreased uterine electromyographic activity in pregnant ewes induced to enter preterm labour with RU486, the progesterone receptor blocker (I.R. Young, personal communication). These studies demonstrate the participation of NF kappa B in preterm labour. Inhibiting NF kappa B should decrease overall PG synthesis and action, but this needs to be demonstrated in the whole animal. Also, the side effects of inhibiting NF kappa B must be determined. 5. It is likely that effective tocolysis may occur using combinations of these approaches which could either utilize lower, less harmful doses of certain inhibitors, or permit arrest of preterm labour at critical windows of development.
THE FUTURE FOR PG-RELATED TOCOLYSIS
Increasingly, strategies for inhibiting PG synthesis or action for the delay of preterm labour are evolving. (Figure 3) The administration of PGHS inhibitors has met with variable success and in most cases, results in fetal side effects, principally decreasing renal urine production. Another target of the PG synthesis-receptor cascade that does have potential as a tocolytic target is antagonizing the action of the PGF 2alpha receptor, FP, as it combines tocolytic effectiveness with minimal side effects. This derives from the fact that PGF 2alpha has relatively few effects in the fetus (or in the mother outside of uterine effects). Arresting cytokine production or activation is clearly an important area for exploration. The tyrphostins (inhibitors of tyrosine kinases) presumably arrest cytokine activation, although this needs to be confirmed in relation to preterm birth. If so, then levels of key cytokines such as IL-1beta, IL-6, IL-8, and TNF-alpha, may be reduced and not able to stimulate PLA 2 , PGHS-2, PG synthases, or PG receptors when tyrphostins are administered. Accumulating evidence demonstrates that an important mechanism of IL1beta, TNF-alpha and perhaps other cytokines, and lipopolysaccharide (LPS), is to stimulate NF kappa B and its upregulation of several components of the PG synthesisreceptor cascade. Targeting NF kappa B would potentially decrease the expression of the PG synthesis-receptor cascade. Lastly, while some of these approaches have concerns regarding fetal or maternal safety, and others have not been studied for their potential side effects, it is likely that investigators will continue to explore their possibilities for prolonging pregnancy because of the central importance of PGs in mediating the final common pathways for preterm birth. We anticipate that investigators will continue to explore the effectiveness of PGHS inhibitors, perhaps testing lower doses, seeking developmental windows where inhibiting fetal PGHS activity and PG synthesis has minimal side effects, administrating drugs intermittently, or possibly combining PGHS-1 and -2-specific inhibitors together or with other inhibitors. These approaches may be the hope for the future of successfully manipulating the PG synthesis-receptor cascade for successful maintenance of pregnancy and delay of preterm birth. 
